Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
16.87
-0.17 (-1.00%)
At close: Feb 21, 2025, 4:00 PM
16.94
+0.07 (0.41%)
After-hours: Feb 21, 2025, 6:35 PM EST
Nurix Therapeutics Employees
Nurix Therapeutics had 286 employees as of November 30, 2024. The number of employees increased by 2 or 0.70% compared to the previous year.
Employees
286
Change (1Y)
2
Growth (1Y)
0.70%
Revenue / Employee
$190,731
Profits / Employee
-$676,815
Market Cap
1.28B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
NRIX News
- 7 days ago - Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 24 days ago - Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation - Seeking Alpha
- 6 weeks ago - Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting - GlobeNewsWire